आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - tetanus toxoid diphtheria toxoid pertussis toxoid filamentous haemagglutinin (fha) pertactin polio virus type 1 inactivated polio virus type 2 inactivated polio virus type 3 inactivated adsorbed fimbriae types 2 + 3 - suspension for injection - %v/v

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - diphtheria toxoid adsorbed tetanus toxoid adsorbed pertussis toxoid adsorbed (pt) filamentous haemagglutinin adsorbed (fha) fimbriae types 2 and 3 adsorbed (fim) pertactin adsorbed (prn) inactivated poliomyelitis vaccine type 1 (mahoney) inactivated poliomyelitis vaccine type 2 (mef-1) inactivated poliomyelitis vaccine type 3 (saukett) haemophilus influenzae b conjugate vaccine (prp-t) conjugated to tenanus protein aluminium phosphate (a1) - suspension for injection

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - diphtheria toxoid adsorbed tetanus toxoid adsorbed pertussis toxoid adsorbed (pt) filamentous haemagglutinin adsorbed (fha) fimbriae types 2 and 3 adsorbed (fim) pertactin adsorbed (prn) inactivated poliomyelitis vaccine type 1 (mahoney) inactivated poliomyelitis vaccine type 2 (mef-1) inactivated poliomyelitis vaccine type 3 (saukett) haemophilus influenzae b conjugate vaccine (prp-t) conjugated to tenanus protein aluminium phosphate (a1) - suspension for injection

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - salmonella typhi, vi antigen - solution for injection - 25/0.5 microgram/ml - typhoid vaccines

ऑस्ट्रेलिया - अंग्रेज़ी - Department of Health (Therapeutic Goods Administration)

sanofi-aventis australia pty ltd - rabies immunoglobulin, quantity: 150 iu/ml - injection - excipient ingredients: glycine; sodium chloride; water for injections - imogam rabies pasteurized is indicated in subjects who are thought to have been exposed to rabies virus, especially cases of major exposure, in accordance with w.h.o. recommendations as specified in the international product information.

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - purified diphtheria toxoid ph. eur., purified tetanus toxoid, adsorbed purified pertussis toxoid, adsorbed purified filamentous haemagglutinin, inactivated poliomyelitis virus ph. eur, inactivated type 1 poliovirus, inactivated type 2 poliovirus, inactivated type 3 poliovirus, haemophilus influenzae type b, conjugate with tetanus protein - powder for suspension for injection - 0 %v/v - bacterial and viral vaccines, combined

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - a/california/7/2009 (h1n1)v like strain (x-179a) a/california/7/2009 (h1n1) - derived strain used nymc x-181 reass b/brisbane/60/2008 - like strain (b/brisbane/60/2008) - suspension for injection - 7.5 mcg ea %v/v

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - measles virus - schwarz strain live attenuated - pdr+solv for susp for inj

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - a/california/7/2009 (h1n1)pdm09 - derived strain used nymc x-179a, a/hong kong/4801/2014 (h3n2) - like strain (a/hong kong/4801/2014, nymc x-263b), b/brisbane/60/2008 - like strain (b/brisbane/60/2008) - suspension for injection - 15/15/15mc %v/v - influenza vaccines

आयरलैंड - अंग्रेज़ी - HPRA (Health Products Regulatory Authority)

sanofi pasteur msd ltd - a/california/7/2009 (h1n1)pdm09 - derived strain used nymc x-179a a/victoria/361/2011 (h3n2) - derived strain used ivr-165 b/massachusetts/2/2012 - suspension for injection - 7.5 mcg ea %v/v